Our attorneys are investigating claims on behalf of individuals who developed Cutaneous T-Cell Lymphoma (CTCL), including Mycosis Fungoides and Sézary Syndrome, after treatment with Dupixent®.
Recent scientific studies have reported a significantly increased incidence of certain T-cell lymphomas among Dupixent users. Lawsuits filed across the country allege that the manufacturers, Sanofi and Regeneron, failed to adequately warn patients and healthcare providers about these risks.
A federal multidistrict litigation (MDL) was created on June 4, 2026, in the United States District Court for the District of New Jersey to coordinate Dupixent lymphoma lawsuits nationwide.
You may be eligible to pursue a claim if:
- You used Dupixent after 2017;
- You were prescribed Dupixent for eczema, asthma, nasal polyps, COPD, eosinophilic esophagitis, or another approved condition;
- You used Dupixent for at least several months;
- You were later diagnosed with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, or Sézary Syndrome;
- You did not have a lymphoma diagnosis before starting Dupixent.
Plaintiffs allege that Dupixent:
- Increased the risk of developing CTCL and related T-cell lymphomas;
- Accelerated or worsened previously undiagnosed CTCL;
- Delayed diagnosis by masking symptoms commonly mistaken for eczema;
- Was marketed without adequate warnings regarding lymphoma risks.
The manufacturers deny these allegations.
Potential claimants should gather:
- Prescription records showing Dupixent use;
- Pharmacy dispensing records;
- Dermatology records;
- Biopsy and pathology reports;
- Oncology records;
- Treatment and staging documentation.
Our legal team can often assist in obtaining many of these records.
Every state imposes deadlines that may limit the time available to file a claim. These deadlines often begin when a person is diagnosed or when they reasonably discover a connection between their diagnosis and Dupixent use.
Because these deadlines vary by state, it is important to have your potential claim reviewed as soon as possible.
If you or a loved one developed Cutaneous T-Cell Lymphoma, Mycosis Fungoides, or Sézary Syndrome after using Dupixent, contact our office today.
Our attorneys are actively reviewing potential claims nationwide.
You May Qualify If:
✓ Used Dupixent after 2017
✓ Diagnosed with CTCL, Mycosis Fungoides, or Sézary Syndrome
✓ No prior lymphoma diagnosis before starting Dupixent
✓ Diagnosis occurred after beginning Dupixent treatment
Don’t wait to seek the justice you deserve. Contact McGartland Law Firm at (866) 832-9300 to learn more about your legal options.
We are committed to holding pharmaceutical companies accountable for putting profits over safety. Let us fight for you.
